Immuron Ltd (stock)

General Information
Business:

(Note: A public offering:Our ordinary shares are listed on the Australian Securities Exchange under the symbol “IMC.” On May 19, 2017, the closing price of our ordinary shares on the Australian Securities Exchange was AUD$0.53 per ordinary share, equivalent to $15.74 per ADS based on an exchange rate of AUD$1.00 to $0.7426 (as published by the Reserve Bank of Australia as of May 19, 2017).

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. Our lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune mediated diseases including fatty-liver diseases.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 8
Founded: 1994
Contact Information
Address Suite 1, 1233 High Street, Armadale, Victoria, Australia 3143
Phone Number +61 (0)3 9824 5254
Web Address https://www.immuron.com
View Prospectus: Immuron Ltd (stock)
Financial Information
Market Cap $66.7mil
Revenues $0.9 mil (last 12 months)
Net Income $-5.8 mil (last 12 months)
IPO Profile
Symbol IMRN
Exchange NASDAQ
Shares (millions): 0.6
Price range $9.99 - $9.99
Est. $ Volume $6.1 mil
Manager / Joint Managers Joseph Gunnar/ Rodman & Renshaw (a unit of H.C. Wainwright & Co.)
CO-Managers WallachBeth Capital
Expected To Trade: 6/9/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change